SG11201810280YA - Spiro-lactam nmda receptor modulators and uses thereof - Google Patents

Spiro-lactam nmda receptor modulators and uses thereof

Info

Publication number
SG11201810280YA
SG11201810280YA SG11201810280YA SG11201810280YA SG11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA SG 11201810280Y A SG11201810280Y A SG 11201810280YA
Authority
SG
Singapore
Prior art keywords
international
pct
compounds
nmda receptor
spiro
Prior art date
Application number
SG11201810280YA
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201662338767P priority Critical
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Priority to PCT/US2017/033323 priority patent/WO2017201283A1/en
Publication of SG11201810280YA publication Critical patent/SG11201810280YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111011101111111111111111111111111111111111111111111111111111111111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date .....0\"\"\" WO 2017/201283 Al 23 November 2017 (23.11.2017) WIPO I PCT (51) International Patent Classification: CO7D 487/10 (2006.01) A61P 25/00 (2006.01) A61K 31/407 (2006.01) (21) International Application Number: PCT/US2017/033323 (22) International Filing Date: 18 May 2017 (18.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/338,767 19 May 2016 (19.05.2016) US (71) Applicant: APTINYX INC. [US/US]; 1801 Maple Av- enue, Suite 4300, Evanston, IL 60201 (US). (72) Inventor: KHAN, M. Amin; 720 Oakton Street #3A, Evanston, IL 60202 (US). (74) Agent: BRODOWSKI, Michael et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, = (81) =_ _ KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, = MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, — = TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every = (84) = = kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = = _ _ TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, = KM, ML, MR, NE, SN, TD, TG). = Published: — with international search report (Art. 21(3)) Il en (54) Title: SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF ot) ei o (57) : Disclosed are compounds having enhanced potency in the modulation of NMDA receptor 1-1 Rd R 2 0 NH 2 activity. Such compounds can be used in the treatment of conditions such as depression and related ei N disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the IN R i N OH compounds, including intravenous formulations, are also disclosed. 1-1 0 ei o -_/ ( 1 ) C
SG11201810280YA 2016-05-19 2017-05-18 Spiro-lactam nmda receptor modulators and uses thereof SG11201810280YA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201662338767P true 2016-05-19 2016-05-19
PCT/US2017/033323 WO2017201283A1 (en) 2016-05-19 2017-05-18 Spiro-lactam nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
SG11201810280YA true SG11201810280YA (en) 2018-12-28

Family

ID=58779357

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201810280YA SG11201810280YA (en) 2016-05-19 2017-05-18 Spiro-lactam nmda receptor modulators and uses thereof

Country Status (18)

Country Link
US (2) US9932347B2 (en)
EP (1) EP3458458B1 (en)
JP (1) JP6823083B2 (en)
KR (1) KR102128675B1 (en)
CN (1) CN109415372B (en)
AU (1) AU2017267708B2 (en)
BR (1) BR112018073663A2 (en)
CA (1) CA3024606C (en)
CL (1) CL2018003265A1 (en)
CO (1) CO2018013747A2 (en)
EA (1) EA201892657A1 (en)
IL (1) IL263045D0 (en)
MX (1) MX2018014202A (en)
PE (1) PE20190174A1 (en)
PH (1) PH12018502438A1 (en)
SG (1) SG11201810280YA (en)
WO (1) WO2017201283A1 (en)
ZA (1) ZA201807731B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2553968T3 (en) 2008-09-18 2015-12-15 Northwestern University NMDA receiver modulators and their uses
LT2951183T (en) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201283A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG11201900551WA (en) 2016-08-01 2019-02-27 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
EP3490990A1 (en) 2016-08-01 2019-06-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
AU2019215049A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2019152681A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2019152696A1 (en) * 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US4904681A (en) 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
CA2058975C (en) 1990-10-30 2000-06-06 Shuichi Kasai Antiinflammatory gel preparation
US5168103A (en) 1991-01-22 1992-12-01 American Home Products Corporation [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl) amino]alkyl]-acid derivatives
FR2692268B1 (en) 1992-06-15 1994-08-19 Rhone Poulenc Rorer Sa New polypeptides having NMDA receptor activity, nucleic acids encoding these polypeptides and uses.
SE9301667D0 (en) 1993-05-14 1993-05-14 Kabi Pharmacia Ab NEW USE
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US5605911A (en) 1995-01-31 1997-02-25 Washington University Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH)
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
US5741778A (en) 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
SK166798A3 (en) 1996-06-07 1999-07-12 Zeneca Ltd Peptide derivatives, process for their preparation, pharmaceutical composition them containing, and their use
US5959075A (en) 1996-08-02 1999-09-28 Zymogenetics, Inc. Testis-specific insulin homolog polypeptides
US5902815A (en) 1996-09-03 1999-05-11 Washington University Use of 5HT-2A serotonin agonists to prevent adverse effects of NMDA receptor hypofunction
JP3955345B2 (en) 1996-09-27 2007-08-08 サントリー株式会社 New amino acid Daiji Harvein
AU1585999A (en) 1997-11-12 1999-05-31 Neurotherapeutics Methods for the detection and treatment of disease using a glycosyltransferase
US5952389A (en) 1998-01-13 1999-09-14 Synchroneuron Methods of treating tardive dyskinesia and other movement disorders
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6274314B1 (en) 1998-04-02 2001-08-14 Nyxis Neurotherapies, Inc. Diagnostic assay for the modified nucleosides pseudouridine, 7-methyladenosine, or 1-methyladenosine
US6197820B1 (en) 1998-04-06 2001-03-06 Uab Research Foundation Use of phenylglycine derivatives to decrease neuronal death caused by brain tumors and brain lesions
US6025471A (en) 1998-06-03 2000-02-15 Deghenghi; Romano Diazaspiro, azepino and azabicyclo therapeutic peptides
AU1724000A (en) 1998-11-12 2000-05-29 Nyxis, Inc. Diagnostic assay for cancer
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU1922301A (en) 1999-11-17 2001-05-30 Nyxis Neurotherapies, Inc. Differential gene expression in cancer
AU782678B2 (en) 2000-02-01 2005-08-18 Agy Therapeutics, Inc. Interaction of NMDA receptor with protein tyrosine phosphatase
WO2001096606A2 (en) 2000-06-14 2001-12-20 Nyxis Neurotherapies, Inc. Identification of genes and compounds for treatment of cancer
WO2001098367A2 (en) 2000-06-22 2001-12-27 Nyxis Neurotherapies, Inc. Neuroactive peptides for treatment of hypoxia and related conditions
GB0018272D0 (en) 2000-07-25 2000-09-13 Vernalis Research Limited Chemical compounds IV
EP1186303A3 (en) 2000-09-06 2003-12-10 Pfizer Products Inc. Pharmaceutical combinations, for the treatment of stroke and traumatic brain injury, containing a neutrophil inhibiting factor and an selective NMDA-NR2B receptor antagonist
IL145209D0 (en) 2000-09-06 2002-06-30 Pfizer Prod Inc Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
EA006489B1 (en) 2000-12-13 2005-12-29 Пфайзер Продактс Инк. Nmda receptor agonist pharmaceutical compositions
AU3660802A (en) 2000-12-14 2002-06-24 Nyxis Neurotherapies Inc High throughput assay to detect inhibitors of the map kinase pathway
US20030065138A1 (en) 2001-03-07 2003-04-03 University Of Utah Research Foundation Linear gamma-carboxyglutamate rich conotoxins
WO2002072609A2 (en) 2001-03-12 2002-09-19 Nyxis Neurotherapies, Inc Neuroactive peptides for prevention and/or treatment of hypoxia and neuropathic pain
WO2003010540A1 (en) 2001-07-25 2003-02-06 Nyxis Neurotherapies, Inc. Method of identifying nmda-related agent
MXPA05000370A (en) 2002-07-05 2005-04-19 Targacept Inc N-aryl diazaspiracyclic compounds and methods of preparation and use thereof.
US7273889B2 (en) 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
WO2005014797A2 (en) 2003-08-08 2005-02-17 The Burnham Institute P16 mediated regulation of nmda receptors
US7662856B2 (en) 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
GB0323204D0 (en) 2003-10-03 2003-11-05 Novartis Ag Organic compounds
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
WO2006034196A1 (en) 2004-09-17 2006-03-30 Lifelike Biomatic Inc. Compositions for enhancing memory and methods therefor
JP5295755B2 (en) 2005-03-24 2013-09-18 エモリー ユニバーシティー Dosing regimen for the treatment of traumatic brain injury with progesterone
US7631994B2 (en) 2005-07-11 2009-12-15 Lights Of America, Inc. Mounting system for a light fixture
WO2007025141A2 (en) 2005-08-26 2007-03-01 Wisconsin Alumni Research Foundation Poly-beta-peptides from functionalized beta-lactam monomers and antibacterial compositions containing same
AR059224A1 (en) 2006-01-31 2008-03-19 Jerini Ag Compounds for the inhibition of integrins and their use
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008033464A2 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
JP2008188285A (en) 2007-02-06 2008-08-21 Bridgestone Corp Back pad and vehicle seat
CN101066945B (en) 2007-05-25 2010-05-19 中国科学院上海有机化学研究所 Process of synthesizing 3-substituted lactan compound
CN101125817B (en) 2007-08-03 2011-09-14 中国科学院上海有机化学研究所 Method for synthesizing aldehyde substituted small ring amines compounds with high enantioselectivity and 3-substituted lactams compounds with optical activity
WO2009039390A2 (en) 2007-09-20 2009-03-26 Naurex Inc. The development of glycobiology-based therapeutics for the treatment of brain tumors
JP6078211B2 (en) 2008-02-20 2017-02-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia Genetic changes associated with autism and the phenotype of autism and its use for diagnosis and treatment of autism
ES2461841T3 (en) 2008-08-07 2014-05-21 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
ES2553968T3 (en) 2008-09-18 2015-12-15 Northwestern University NMDA receiver modulators and their uses
WO2010065709A2 (en) 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
DE102009001460B4 (en) 2009-03-11 2010-12-02 Zf Friedrichshafen Ag oilcontainer
US20120178695A1 (en) 2009-07-02 2012-07-12 Joseph Moskal Methods of treating neuropathic pain
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
ES2493316T3 (en) 2009-10-05 2014-09-11 Northwestern University GLYX-13 for use in a method to treat depression that does not respond to treatment
KR101692275B1 (en) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 Secondary structure stabilized nmda receptor modulators and uses thereof
CA2789331C (en) 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
EP2701721A4 (en) 2011-04-27 2015-12-16 Univ Northwestern Methods of treating alzheimer's disease, huntington's disease, autism, or other disorders
JP6388536B2 (en) 2011-06-27 2018-09-12 コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. Ultrasonic vibrator assembly and manufacturing method thereof
EP3333161B1 (en) 2011-07-27 2020-02-19 Astrazeneca AB 2-(2,4,5-substituted-anilino)pyrimidine derivatives as egfr modulators useful for treating cancer
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US9708335B2 (en) 2013-01-29 2017-07-18 Apytinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
CA2899010A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP6419087B2 (en) 2013-01-29 2018-11-07 アプティニックス インコーポレイテッド Spirolactam NMDA receptor modulator and use thereof
LT2951183T (en) 2013-01-29 2019-05-27 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20151427A1 (en) 2013-01-29 2015-10-10 Naurex Inc SPIRO-LACTAMA NMDA RECEIVER MODULATORS AND THEIR USES
WO2017201283A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof

Also Published As

Publication number Publication date
US9932347B2 (en) 2018-04-03
JP6823083B2 (en) 2021-01-27
JP2019516735A (en) 2019-06-20
ZA201807731B (en) 2019-08-28
IL263045D0 (en) 2018-12-31
EP3458458B1 (en) 2020-11-04
CA3024606C (en) 2019-09-03
PH12018502438A1 (en) 2019-09-09
US20170334922A1 (en) 2017-11-23
MX2018014202A (en) 2019-06-20
AU2017267708B2 (en) 2020-02-20
CO2018013747A2 (en) 2019-01-18
KR102128675B1 (en) 2020-06-30
KR20190010613A (en) 2019-01-30
PE20190174A1 (en) 2019-02-01
CL2018003265A1 (en) 2019-01-25
EA201892657A1 (en) 2019-05-31
AU2017267708A1 (en) 2018-12-06
US10196401B2 (en) 2019-02-05
EP3458458A1 (en) 2019-03-27
CA3024606A1 (en) 2017-11-23
BR112018073663A2 (en) 2019-04-30
WO2017201283A1 (en) 2017-11-23
CN109415372A (en) 2019-03-01
US20180093994A1 (en) 2018-04-05
CN109415372B (en) 2021-01-15

Similar Documents

Publication Publication Date Title
SG11201810171SA (en) Kras g12c inhibitors
SG11201901700UA (en) Biaryl compounds useful as immunomodulators
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201806801VA (en) Securely attaching cartridges for vaporizer devices
SG11201906373VA (en) Chemical compounds as inhibitors of interleukin-1 activity
SG11201901445TA (en) A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
SG11201908670SA (en) Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
SG11201804915RA (en) Methods for treating huntington's disease
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201808907PA (en) Inhibitors of activin receptor-like kinase
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804934PA (en) Novel Compounds
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201408054RA (en) Pegylated oxm variants
SG11201803686UA (en) Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201900799XA (en) Pyridopyrimdinone cdk2/4/6 inhibitors
SG11201909274WA (en) Annular motion simulation amusement park attraction